argenx NV ADR (ARGX)vsKymera Therapeutics Inc (KYMR)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
KYMR
Kymera Therapeutics Inc
$122.51
+4.20%
HEALTHCARE · Cap: $8.62B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 5534% more annual revenue ($5.92B vs $105.00M). ARGX leads profitability with a 31.7% profit margin vs -285.3%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
KYMR
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Margin of Safety
+23.4%
Fair Value
$107.41
Current Price
$122.51
$15.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 466.4% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
0.0% earnings growth
Weak financial health signals
ROE of -20.5% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 466.4% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while KYMR is a hypergrowth play — different risk/reward profiles.
KYMR carries more volatility with a beta of 1.98 — expect wider price swings.
KYMR is growing revenue faster at 466.4% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 30/100), backed by strong 31.7% margins and 52.1% revenue growth. KYMR offers better value entry with a 23.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?